Although TP53 exhibits a dual role in regulating cancer cell sensitivity to ferroptosis, targeting the p53-ferroptosis pathway remains a superior therapeutic option compared to other targeted factors, given the potent tumor-suppressive functions of p53 across various cancers [29]. This evidence concerns the gene TP53 and neoplasm.